Shareholders’ (Deficiency) Equity (Tables)

12 Months Ended

Dec. 31, 2022

Stockholders' Equity Note [Abstract]

Schedule of consolidated financial statements

	December 31, 2021				December 31, 2022
	Authorized		Issued and outstanding		Authorized		Issued and outstanding
	Number of shares
Ordinary shares of no-par value *)		72,423,360		40,528,913		362,116,800		69,105,000

*) Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March 7, 2022.

Schedule of the status of options and changes

	Year ended December 31, 2022
Employees	Number of options			Weighted average exercise price		Aggregate intrinsic value		Weighted average remaining contractual life (years)
Outstanding at beginning of year		5,325,572		$	4.97	$	17,854		7.42
Granted		2,017,144		$	8.57
Exercised		(24,100	)	$	1.12
Transfer between employee and service provider		(505,265	)	$	3.91
Forfeited and cancelled		(187,832	)	$	8.02
Outstanding at end of year		6,625,519		$	6.08	$	1,743		7.39
Exercisable options		3,931,292		$	4.33	$	1,740		6.35

			Year ended December 31, 2022
Service providers	Number of options		Weighted average exercise price		Aggregate intrinsic value		Weighted average remaining contractual life (years)
Outstanding at beginning of year		721,197	$	4.34	$	2,695		6.61
Granted		385,813	$	5.53
Exercised		-		-
Transfer between employee and service provider		505,265	$	3.91
Forfeited and cancelled		-		-
Outstanding at end of year		1,612,275	$	4.49	$	845		6.60
Exercisable options		1,116,997	$	3.58	$	845		5.32

Schedule of summary of the status of RSUs under the plan

	Number of RSU
Outstanding at beginning of year		1,031,250
Granted		154,891
Vested		(232,360	)
Forfeited and cancelled		(28,914	)
Outstanding at end of year		924,867

Schedule of total equity-based compensation expense

	Year ended December 31,
	2020		2021		2022
Research and development	$	372	$	654	$	4,289
Marketing expenses		20		7		210
General and administrative		204		151		2,249
Total share-based compensation expense	$	596	$	812	$	6,748